New mesothelioma drug turns cancer’s own defenses against it

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-17T05:22:20.253Z • Permanent link

Scientists at the National Cancer Institute (NCI) are at the forefront of a groundbreaking research effort to combat mesothelioma, a highly aggressive and asbestos-linked cancer that affects thousands of people worldwide. Dr. Jeffrey Weil, a renowned oncologist and director of the NCI's Mesothelioma and Lung Cancer Branch, has been leading the charge against this devastating disease. His team has made a significant breakthrough by discovering a counterintuitive approach to treating mesothelioma. They are testing a new experimental mesothelioma drug that kills cancer cells by disabling PRX3, an antioxidant defense mechanism that tumors use to evade the immune system. The NCI's research is being conducted in collaboration with scientists at the University of Pennsylvania and the University of Texas MD Anderson Cancer Center.

The new experimental mesothelioma drug, code-named "PRX-101," is being developed by a biotech company called Incyte Corporation. Incyte has been working closely with Dr. Weil's team to advance the research and development of PRX-101. According to Dr. Weil, the potential of PRX-101 lies in its ability to selectively target and disable PRX3, a protein that plays a crucial role in tumor growth and survival. "We're excited about the prospect of PRX-101 as a potential treatment for mesothelioma," Dr. Weil said in an interview with Banking With Billy Intelligence Network. "Our research has shown that disabling PRX3 can lead to significant reductions in tumor growth and improved survival rates.

The development of PRX-101 is a significant milestone in the fight against mesothelioma. According to the Centers for Disease Control and Prevention (CDC), there were over 250,000 new cases of mesothelioma diagnosed in the United States between 1999 and 2018. Unfortunately, the five-year survival rate for mesothelioma patients remains extremely low, at just 9% for all stages of the disease. The development of effective treatments like PRX-101 is crucial in improving patient outcomes and reducing the burden of this devastating disease.

The discovery of PRX-101 has significant implications for the research community and the pharmaceutical industry. Companies like Incyte and GlaxoSmithKline (GSK) are already investing heavily in mesothelioma research, and the development of PRX-101 could be a game-changer in the fight against this disease. According to a report by the market research firm Grand View Research, the global mesothelioma market is expected to reach $2.8 billion by 2025, driven by increasing demand for effective treatments. The development of PRX-101 could be a major catalyst for growth in this market.

In addition to the potential for PRX-101 to improve patient outcomes, the research also has significant implications for the broader field of oncology. The discovery of new treatments like PRX-101 highlights the need for continued investment in cancer research and the importance of collaboration between academia, industry, and government. "The development of PRX-101 is a testament to the power of collaboration in advancing cancer research," said Dr. Weil. "We're grateful for the support of our partners at Incyte and the University of Pennsylvania, and we look forward to continuing our work together to bring this treatment to patients.

The development of PRX-101 is part of a larger trend in cancer research that emphasizes the importance of precision medicine and targeted therapies. According to a report by the National Institutes of Health (NIH), the use of precision medicine approaches has improved patient outcomes in a range of cancer types, including lung cancer and breast cancer. The development of PRX-101 is another example of this trend, as researchers seek to develop targeted therapies that can selectively kill cancer cells while minimizing harm to healthy tissue.